Scholarlink

Background <p>The cytokine storm is a pivotal factor in the progression of coronavirus disease 2019 (COVID-19) to severe disease. Sivelestat, recognized for its anti-inflammatory properties, holds promise as a therapeutic intervention for patients with severe COVID-19.</p> Methods <p>We conducted a multicenter, retrospective study involving patients admitted to the intensive care unit (ICU) with severe COVID-19 in China. A 1:2 propensity score matching (PSM) was employed to adjust for confounding factors and differences between the sivelestat and non-sivelestat groups.</p> Results <p>Our analysis involved 2030 patients with severe COVID-19. After applying a 1:2 PSM ratio, the sivelestat group consisted of 115 patients, while the non-sivelestat group comprised 211 patients. The findings indicated that sivelestat administration was associated with enhanced survival rates at 28 days for patients with severe COVID-19 (53.55% vs. 40.87%; <i>P</i> = 0.03). However, no significant differences were noted in the secondary outcomes, which included ventilator-free days within 28 days, gastrointestinal bleeding, septic shock, acute myocardial injury, venous thrombosis, acute liver injury, and acute kidney injury. Furthermore, this study revealed that early administration of sivelestat could reduce patient mortality.</p> Conclusions <p>Our study suggests that sivelestat use may be associated with reduced 28-day mortality in ICU patients with severe COVID-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and optimal timing of sivelestat in critically ill patients with COVID-19: a multicenter retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Qi Zhang,
  • Yijie Liu,
  • Bowen Ran,
  • Tianshu Zhai,
  • Ying Cai,
  • Chao Zhang,
  • Jingcheng Hao,
  • Longxian Jin,
  • Zhenyuan Huang,
  • Xiaojing Wu,
  • Qingyuan Zhan

摘要

Background

The cytokine storm is a pivotal factor in the progression of coronavirus disease 2019 (COVID-19) to severe disease. Sivelestat, recognized for its anti-inflammatory properties, holds promise as a therapeutic intervention for patients with severe COVID-19.

Methods

We conducted a multicenter, retrospective study involving patients admitted to the intensive care unit (ICU) with severe COVID-19 in China. A 1:2 propensity score matching (PSM) was employed to adjust for confounding factors and differences between the sivelestat and non-sivelestat groups.

Results

Our analysis involved 2030 patients with severe COVID-19. After applying a 1:2 PSM ratio, the sivelestat group consisted of 115 patients, while the non-sivelestat group comprised 211 patients. The findings indicated that sivelestat administration was associated with enhanced survival rates at 28 days for patients with severe COVID-19 (53.55% vs. 40.87%; P = 0.03). However, no significant differences were noted in the secondary outcomes, which included ventilator-free days within 28 days, gastrointestinal bleeding, septic shock, acute myocardial injury, venous thrombosis, acute liver injury, and acute kidney injury. Furthermore, this study revealed that early administration of sivelestat could reduce patient mortality.

Conclusions

Our study suggests that sivelestat use may be associated with reduced 28-day mortality in ICU patients with severe COVID-19.